Drug Profile
Androgen tear
Latest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator Allergan
- Class Eye disorder therapies; Glucans; Glycerides
- Mechanism of Action Androgen receptor modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Dry eyes
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 05 Apr 2011 Development discontinued for Dry eyes before April 2011
- 28 Apr 2008 Phase-II clinical trials in Dry eyes in USA (Intraocular)